Biodesix, Inc. Common Stock
BDSX US09075X1081
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -73% | -60% | -10% | -14% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Schuler Jack W |
7.04 USD |
142,045 Bought |
999,997 USD |
19/09/2025 | 19/09/2025 |
| Schuler Jack W |
6.17 USD |
3,056 Bought |
18,854 USD |
17/09/2025 | 18/09/2025 |
| Schuler Jack W |
6.04 USD |
15,317 Bought |
92,571 USD |
17/09/2025 | 17/09/2025 |
| Schuler Jack W |
0.43 USD |
3,488,372 Bought |
1,500,000 USD |
29/08/2025 | 29/08/2025 |
| Cowie Robin Harper CFO |
0.42 USD |
988 Sold |
411 USD |
12/08/2025 | 13/08/2025 |
| Vazquez Chris CCO |
0.42 USD |
228 Sold |
95 USD |
12/08/2025 | 13/08/2025 |
| Pestano Gary Anthony BDM |
0.42 USD |
442 Sold |
184 USD |
12/08/2025 | 13/08/2025 |
| Hutton Scott CEO |
0.42 USD |
3,772 Sold |
1,570 USD |
12/08/2025 | 13/08/2025 |
| O'kane Kieran CCO |
0.42 USD |
476 Sold |
198 USD |
12/08/2025 | 13/08/2025 |
| Schuler Jack W |
0.34 USD |
723,239 Bought |
246,625 USD |
16/05/2025 | 19/05/2025 |